Employing genetic engineering for the treatment of infectious diseases means introducing specific genes that discretely inhibit or block the functions of target genes.
Chronic and especially cardiometabolic diseases are the culmination of multiple risk factors ranging from genetic predispositions and sedentary lifestyles to stress.
E. Charpentier and A. Doudna have made a landmark discovery for the CRISPR/Cas 9 method employed in genome editing, and received 2020's Nobel prize in chemistry.
